Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences Co., Ltd. announced a change in equity holdings, where the shareholders holding more than 5% of the company’s shares, including Shanghai Tanying Investment Partnership and its concerted parties, have reduced their total equity proportion from 8.96% to 7.91%. This change does not breach any commitments or trigger a mandatory tender offer obligation, indicating a strategic adjustment in shareholder structure without significant implications for the company’s operational commitments or market positioning.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative therapies. The company operates in the biotechnology industry, primarily dealing with the research and development of drugs for various medical conditions, aiming to address unmet medical needs.
Average Trading Volume: 13,833,980
Technical Sentiment Signal: Buy
Current Market Cap: HK$48.71B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.